MARKET

EPZM

EPZM

Epizyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.59
-0.07
-0.72%
After Hours: 9.59 0 0.00% 17:03 02/26 EST
OPEN
9.72
PREV CLOSE
9.66
HIGH
9.86
LOW
9.42
VOLUME
1.16M
TURNOVER
--
52 WEEK HIGH
23.61
52 WEEK LOW
9.42
MARKET CAP
976.12M
P/E (TTM)
-4.1808
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25)
Benzinga · 8h ago
Epizyme downgraded at Morgan Stanley citing pandemic impact
Morgan Stanley has downgraded Epizyme ([[EPZM]] -1.8%) to equal-weight from overweight, The firm highlights the pandemic impact on Tazverik market launch with the price target cut to ~$14.00 from $27.00
Seekingalpha · 1d ago
Benzinga's Top Ratings Upgrades, Downgrades For February 25, 2021
Upgrades For Lowe's Companies Inc (NYSE:LOW), Gordon Haskett upgraded the previous rating of Accumulate to Buy. Lowe's Companies earned $1.33 in the fourth quarter, compared to $0.94 in the year-ago quarter. At the moment, the stock has a 52-week-high of $...
Benzinga · 1d ago
DJ Epizyme Cut to Equal-Weight From Overweight by Morgan Stanley
Dow Jones · 1d ago
DJ Epizyme Price Target Announced at $14.00/Share by Morgan Stanley
Dow Jones · 1d ago
Morgan Stanley Downgrades Epizyme to Equal-Weight, Announces $14 Price Target
Morgan Stanley analyst David Lebowitz downgrades Epizyme (NASDAQ:EPZM) from Overweight to Equal-Weight and announces $14 price target.
Benzinga · 1d ago
Cell Separation and Characterization in Solid Tumors Market Recent Trends, In-depth Analysis, Market Size Research Report Forecast up to 2025
Feb 25, 2021 (Heraldkeepers) -- The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global...
Heraldkeepers · 1d ago
--Analyst Actions: Morgan Stanley Downgrades Epizyme to Equal-Weight From Overweight; Price Target is $14
MT Newswires · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EPZM. Analyze the recent business situations of Epizyme through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EPZM stock price target is 19.63 with a high estimate of 36.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 259
Institutional Holdings: 107.58M
% Owned: 105.91%
Shares Outstanding: 101.79M
TypeInstitutionsShares
Increased
47
6.92M
New
48
2.23M
Decreased
41
2.48M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Independent Director
David Mott
President/Chief Executive Officer/Director
Robert Bazemore
Chief Financial Officer
Paolo Tombesi
Chief Scientific Officer
Jeffery Kutok
Other
Shefali Agarwal
Other
Matthew Ros
Director
Michael Giordano
Director
Pablo Legorreta
Independent Director
Andrew Allen
Independent Director
Kenneth Bate
Independent Director
Grant Bogle
Independent Director
Kevin Conroy
Independent Director
Carl Goldfischer
Independent Director
Victoria Richon
  • Dividends
  • Splits
  • Insider Activity
No Data
About EPZM
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.

Webull offers kinds of Epizyme Inc stock information, including NASDAQ:EPZM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EPZM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EPZM stock methods without spending real money on the virtual paper trading platform.